Rechallenge with docetaxel after a first response in metastatic breast cancer: A significant activity with manageable toxicity.

e11557 Background: Docetaxel (Dc) is a major drug in metastatic breast cancer (MBC). At progression, rechallenge with docetaxel can be discussed based on the previous efficacy and tolerance. No data on this pragmatic strategy are avalaible in MBC. Methods: We identify 73 patients (pts) with the following criteria: (i) objective response or stable disease with a previous line of treatment with Dc in MBC, (ii) rechallenge with Dc (on a three weekly schedule) for progressive disease after a minimal Dc-free interval of 3 months. The main objectives were to evaluate the overall response, the time to progression (TTP) and toxicity at reintroduction of TXT. Results: Median age was 57 years (34 - 84). Patients had already received 1, 2, 3, ≥ 4 lines of chemotherapy (including the first use of Dc) in 20%, 47%, 18% and 15% of cases, including capecitabine, anthracycline, and vinorelbine in 56%, 40% and 21% of cases, respectively. Visceral disease was described in 80% of cases. The median number of cycles was 6 (1-1...